Literature DB >> 3569007

Synergy of fosfomycin with beta-lactam antibiotics against staphylococci and aerobic gram-negative bacilli.

N X Chin, N M Neu, H C Neu.   

Abstract

Fosfomycin inhibits bacterial cell wall synthesis at the initial stage. It can act synergistically with beta-lactams. The effect of the combination of fosfomycin and selected penicillins and cephalosporins against staphylococci, Pseudomonas aeruginosa, Pseudomonas cepacia and selected Gram-negative bacteria was determined. Synergy was determined by agar dilution and checkerboard titration methods; synergy was defined as an FIC index less than or equal to 0.5 and partial synergy greater than 0.5 to 0.75. Concentrations of drugs used were those that would be reached in man by intravenous and oral routes. Fosfomycin combined with nafcillin and with cefotaxime against staphylococci showed synergy for most isolates. For methicillin-resistant Staphylococcus aureus, synergy or partial synergy was found for 90% of isolates. Synergy was less frequently found with Staphylococcus epidermidis. The MICs for S. aureus were reduced from greater than or equal to 32 micrograms/ml to less than or equal to 1 microgram/ml. Fosfomycin was synergistic with ticarcillin, piperacillin, azlocillin, ceftazidime, aztreonam and imipenem against 31 to 61% of P. aeruginosa. MICs were reduced from greater than or equal to 128 micrograms/ml to 8-32 micrograms/ml, depending upon the agent. Although fosfomycin acted synergistically with azlocillin, piperacillin and ceftazidime against some P. cepacia, most often there was an indifferent interaction and MICs were in the resistant range, greater than or equal to 128 micrograms/ml. The interaction of fosfomycin and ampicillin was synergistic against a number of strains of Enterobacteriaceae, Proteus vulgaris and Providencia rettgeri, yielding MICs in an achievable range. The combination of fosfomycin with beta-lactams may be clinically useful in selected situations, particularly for methicillin-resistant staphylococci and beta-lactam-resistant P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3569007

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  8 in total

1.  In vitro synergistic activity between meropenem and other beta-lactams against methicillin-resistant Staphylococcus aureus.

Authors:  Y Sumita; S Mitsuhashi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

2.  Effect of different combinations of sparfloxacin, oxacillin, and fosfomycin against methicillin-resistant staphylococci.

Authors:  A Ferrara; C Dos Santos; M Cimbro; G Gialdroni Grassi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-07       Impact factor: 3.267

3.  In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.

Authors:  F Tessier; C Quentin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-02       Impact factor: 3.267

4.  Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.

Authors:  Alexandro Rodríguez-Rojas; María D Maciá; Alejandro Couce; Cristina Gómez; Alfredo Castañeda-García; Antonio Oliver; Jesús Blázquez
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

5.  The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa.

Authors:  Alfredo Castañeda-García; Alexandro Rodríguez-Rojas; Javier R Guelfo; Jesús Blázquez
Journal:  J Bacteriol       Date:  2009-09-04       Impact factor: 3.490

6.  Comparison of the essential cellular functions of the two murA genes of Bacillus anthracis.

Authors:  G C Kedar; Vickie Brown-Driver; Daniel R Reyes; Mark T Hilgers; Mark A Stidham; Karen Joy Shaw; John Finn; Robert J Haselbeck
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

7.  Fosfomycin tromethamine. Antibiotic of choice in the female patient: A multicenter study.

Authors:  Abdul Rouf Khawaja; Farzana Bashir Khan; Tanveer Iqbal Dar; Arif Hameed Bhat; Mohd Saleem Wani; Baldev Singh Wazir
Journal:  Cent European J Urol       Date:  2015-10-15

Review 8.  Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy.

Authors:  J Mensa; J Barberán; A Soriano; P Llinares; F Marco; R Cantón; G Bou; J González Del Castillo; E Maseda; J R Azanza; J Pasquau; C García-Vidal; J M Reguera; D Sousa; J Gómez; M Montejo; M Borges; A Torres; F Alvarez-Lerma; M Salavert; R Zaragoza; A Oliver
Journal:  Rev Esp Quimioter       Date:  2018-02-23       Impact factor: 1.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.